Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

References

• Kaze AD, Ilori T, Jaar BG, Echouffo-Tcheugui JB. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. BMC Nephrol. 2018;19(1):125. doi:10.1186/s12882-018-0930-5
   PubMed Web of Science ®Google Scholar
• Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15. doi:10.5414/cnp74s085
   PubMed Web of Science ®Google Scholar
• Shaheen FAM, Souqiyyeh MZ. Kidney health in the Middle East. Clin Nephrol. 2010;74(Suppl 1):S85–88. doi:10.5414/cnp74s085
   PubMedGoogle Scholar
• Al-Ghamdi SMG, Bieber B, AlRukhaimi M, et al. Diabetes prevalence, treatment, control, and outcomes among hemodialysis patients in the Gulf cooperation council countries. Kidney Int Rep. 2022;7(5):1093–1102. doi:10.1016/j.ekir.2022.02.012
   PubMedGoogle Scholar
• Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694–700. doi:10.2337/dc15-2322
   PubMed Web of Science ®Google Scholar
• Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825–1833. doi:10.1681/ASN.2013090965
   PubMed Web of Science ®Google Scholar
• Mima A, Yasuzawa T, King GL, Ueshima S. Obesity‐associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018;8(4):664–670. doi:10.1002/2211-5463.12400
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Furth SL, Zoccali C. Obesity and Kidney Disease. Can J Kidney Health Dis. 2017;4:2054358117698669. doi:10.1177/2054358117698669
   Google Scholar
• Ricardo AC, Anderson CA, Yang W, et al. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2015;65(3):412–424. doi:10.1053/j.ajkd.2014.09.016
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–754. doi:10.1016/S2213-8587(21)00242-4
   PubMed Web of Science ®Google Scholar
• Sasso FC, Simeon V, Galiero R, et al. The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial. Cardiovasc Diabetol. 2022;21(1):235. doi:10.1186/s12933-022-01674-7
   PubMed Web of Science ®Google Scholar
• Mima A, Qi W, King GL. Implications of Treatment That Target Protective Mechanisms Against Diabetic Nephropathy. Semin Nephrol. 2012;32(5):471–478. doi:10.1016/j.semnephrol.2012.07.010
   PubMed Web of Science ®Google Scholar
• Tabit CE, Shenouda SM, Holbrook M, et al. Protein Kinase-C Beta Contributes to Impaired Endothelial Insulin Signaling in Humans with Diabetes Mellitus. Circulation. 2013;127(1):86–95. doi:10.1161/CIRCULATIONAHA.112.127514
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Staplin N, Roddick AJ, Emberson J, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41:101163. doi:10.1016/j.eclinm.2021.101163
   PubMedGoogle Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Shabaka A, Cases-Corona C, Fernandez-Juarez G. Therapeutic insights in chronic kidney disease progression. Front Med. 2021;8:645187. doi:10.3389/fmed.2021.645187
   Web of Science ®Google Scholar
• Ameh OI, Ekrikpo U, Bello A, Okpechi I. Current management strategies of chronic kidney disease in resource-limited countries. Int J Nephrol Renov Dis. 2020;13:239–251. doi:10.2147/IJNRD.S242235
   PubMed Web of Science ®Google Scholar
• Ravera M, Noberasco G, Weiss U, et al. CKD awareness and blood pressure control in the primary care hypertensive population. Am J Kidney Dis. 2011;57(1):71–77. doi:10.1053/j.ajkd.2010.08.022
   PubMed Web of Science ®Google Scholar
• Nichols GA, Déruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020;21(1):167. doi:10.1186/s12882-020-01792-y
   PubMed Web of Science ®Google Scholar
• Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. doi:10.1016/S2213-8587(15)00040-6
   PubMed Web of Science ®Google Scholar
• El Achhab Y, Nazek L, Maalej M, Alami M, Nejjari C. Prevalence, control and risk factors related to hypertension among Moroccan adults: a multicentre study. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2019;25(7):447–456. doi:10.26719/emhj.18.057
   Google Scholar
• Benghanem Gharbi M, Elseviers M, Zamd M, et al. Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid “over”- and “under”-diagnosis of CKD. Kidney Int. 2016;89(6):1363–1371. doi:10.1016/j.kint.2016.02.019
   PubMed Web of Science ®Google Scholar
• Thomas B, Matsushita K, Abate KH, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28(7):2167–2179. doi:10.1681/ASN.2016050562
   PubMed Web of Science ®Google Scholar
• Kondo M, Yamagata K, Ling HS, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16(2):279–291. doi:10.1007/s10157-011-0567-1
   PubMed Web of Science ®Google Scholar
• Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrol Carlton Vic. 2019;24(1):56–64. doi:10.1111/nep.13203
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: standards of Medical Care in Diabetes—2023. Diabetes Care. 2021;46(Supplement_1):S191–S202. doi:10.2337/dc23-S011
   Google Scholar
• Kidney Health Australia. Chronic Kidney Disease (CKD) Management in Primary Care; 2020. Available from: https://kidney.org.au/uploads/resources/CKD-Management-in-Primary-Care_handbook_2020.1.pdf. Accessed May 24, 2022.
   Google Scholar
• KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease; 2012. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed August 2, 2022.
   Google Scholar
• Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;99(1):34–47. doi:10.1016/j.kint.2020.10.012
   PubMed Web of Science ®Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2014;63(5):713–735. doi:10.1053/j.ajkd.2014.01.416
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharma India. Indian Society of Nephrology (ISN) and AstraZeneca India join hands this World Kidney Day to fulfil the theme of “Kidney Health for All”. Available from: https://www.prnewswire.com/in/news-releases/indian-society-of-nephrology-isn-and-astrazeneca-india-join-hands-this-world-kidney-day-to-fulfil-The-theme-of-kidney-health-for-all--893523744.html. Accessed August 22, 2022.
   Google Scholar
• Al-Ghamdi S, Abu-Alfa A, Alotaibi T, et al. Chronic Kidney Disease Management in the Middle East and Africa: concerns, Challenges, and Novel Approaches. Int J Nephrol Renov Dis. 2023;16:103–112. doi:10.2147/IJNRD.S363133
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35. doi:10.1016/S2213-8587(19)30384-5
   PubMed Web of Science ®Google Scholar
• Nagasu H, Yano Y, Kanegae H, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database. Diabetes Care. 2021;44(11):2542–2551. doi:10.2337/dc21-1081
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I, Leiter LA, et al. renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58. Diabetes Care. 2021;44(5):1159–1167. doi:10.2337/dc20-2492
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. doi:10.1056/NEJMoa2004967
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
   PubMed Web of Science ®Google Scholar
• Pasternak B, Wintzell V, Melbye M, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. THE BMJ. 2020;369:m1186. doi:10.1136/bmj.m1186
   PubMed Web of Science ®Google Scholar
• Mima A. Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022;8(2):e08878. doi:10.1016/j.heliyon.2022.e08878
   PubMed Web of Science ®Google Scholar
• Mima A. A Narrative Review of Diabetic Kidney Disease: previous and Current Evidence-Based Therapeutic Approaches. Adv Ther. 2022;39(8):3488–3500. doi:10.1007/s12325-022-02223-0
   PubMed Web of Science ®Google Scholar
• Mima A. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Adv Ther. 2021;38(5):2201–2212. doi:10.1007/s12325-021-01735-5
   PubMed Web of Science ®Google Scholar
• Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications. 2018;32(7):720–725. doi:10.1016/j.jdiacomp.2018.04.011
   PubMed Web of Science ®Google Scholar
• Oshima M, Neuen BL, Li J, et al. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: a Post Hoc Analysis from the CREDENCE Trial. J Am Soc Nephrol JASN. 2020;31(12):2925–2936. doi:10.1681/ASN.2020050723
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation. 2020;141(2):100–111. doi:10.1161/CIRCULATIONAHA.119.044133
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Vart P, et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021;44(8):1894–1897. doi:10.2337/dc21-0300
   PubMed Web of Science ®Google Scholar
• Provenzano M, Jongs N, Vart P, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436–443. doi:10.1016/j.ekir.2021.12.013
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134(10):752–772. doi:10.1161/CIRCULATIONAHA.116.021887
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Repetto E, Wheeler DC, et al. Impact of cardio-renal-metabolic comorbidities on cardiovascular outcomes and mortality in type 2 diabetes mellitus. Am J Nephrol. 2020;51(1):74–82. doi:10.1159/000504558
   PubMed Web of Science ®Google Scholar
• Liu T, Li R, Wang X, Gao X, Zhang X. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: a systemic review and meta-analysis. Med Clin. 2021;S0025-7753(21):647. doi:10.1016/j.medcli.2021.09.031
   Google Scholar
• Zhou Z, Chaudhari P, Yang H, et al. Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2017;8(3):555–571. doi:10.1007/s13300-017-0256-5
   Google Scholar
• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–1162. doi:10.1001/archinternmed.2009.132
   PubMed Web of Science ®Google Scholar
• Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 2005;62(16):1663–1682. doi:10.2146/ajhp040300
   PubMed Web of Science ®Google Scholar
• Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif. 2017;43(1–3):179–188. doi:10.1159/000452725
   PubMed Web of Science ®Google Scholar
• Luo J, Brunelli SM, Jensen DE, Yang A. between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11(1):90–100. doi:10.2215/CJN.01730215
   PubMed Web of Science ®Google Scholar
• Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci. 2020;21(21):7833. doi:10.3390/ijms21217833
   PubMed Web of Science ®Google Scholar
• Dalal R, Bruss ZS, Sehdev JS. Physiology, Renal Blood Flow and Filtration. Treasure Island (FL): StatPearls Publishing; 2022. http://www.ncbi.nlm.nih.gov/books/NBK482248/. Accessed 25 May 2022.
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease; 2022. Available from: https://kdigo.org/wp-content/uploads/2022/03/KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf. Accessed May 24, 2022.
   Google Scholar
• The National Institute for Health and Care Excellence (NICE). Recommendations | dapagliflozin for treating chronic kidney disease | guidance. Available from: https://www.nice.org.uk/guidance/ta775/chapter/1-Recommendations. Accessed May 25, 2022.
   Google Scholar
• Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):S1–87. doi:10.1016/j.kint.2020.11.003
   PubMed Web of Science ®Google Scholar
• Mende CW. Chronic kidney disease and SGLT2 Inhibitors: a review of the evolving treatment landscape. Adv Ther. 2022;39(1):148–164. doi:10.1007/s12325-021-01994-2
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Long A, Salvo M. Finerenone: a novel mineralocorticoid receptor antagonist for cardiorenal protection in CKD and T2DM. Ann Pharmacother. 2022;10600280211059576. doi:10.1177/10600280211059577
   Web of Science ®Google Scholar
• Jiang X, Zhang Z, Li C, et al. Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: a Systematic Review Incorporating an Indirect Comparisons Meta-Analysis. Front Pharmacol. 2022;13:896947. doi:10.3389/fphar.2022.896947
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet Lond Engl. 2019;393(10184):1937–1947. doi:10.1016/S0140-6736(19)30772-X
   PubMed Web of Science ®Google Scholar
• McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: nationwide Cohort Study. Diabetes Technol Ther. 2019;21(12):702–712. doi:10.1089/dia.2019.0213
   PubMed Web of Science ®Google Scholar
• Lam D, Shaikh A. Real-Life Prescribing of SGLT2 Inhibitors: how to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics. Kidney360. 2021;2(4):742–746. doi:10.34067/KID.0000412021
   PubMedGoogle Scholar
• Rivera AV, Wang XA, Grodsky M, Gandhi S, Karaisz F, Y LEV. 1499-PUB: increasing Utilization of SGLT2 Inhibitors for Cardiac Patients. Diabetes. 2022;71(Supplement_1):1499–PUB. doi:10.2337/db22-1499-PUB
   Google Scholar
• Ng NM, Ng YS, Chu TK, Lau P. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. BMC Prim Care. 2022;23(1):317. doi:10.1186/s12875-022-01928-z
   PubMedGoogle Scholar
• Warden BA, Steiner J, Camacho A, et al. Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: a collaborative clinical practice statement. Am J Prev Cardiol. 2021;6:100183. doi:10.1016/j.ajpc.2021.100183
   PubMedGoogle Scholar